Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

Speciality: Oncology

Description:

Welcome to today’s session, where we dive into one of the most critical aspects of leukemia management - early relapse in B-cell Acute Lymphoblastic Leukemia (B-cell ALL). I’m Dr. Nitin Gupta, joined by Dr. Eesha Kaul and Dr. Riyaz Ahmad. Together, we’ll unpack the challenges and insights surrounding relapse in B-cell ALL. With our collective expertise in hematology, oncology, and stem cell transplantation, we aim to offer a comprehensive understanding that supports both clinicians and patients in making informed decisions.

B-cell ALL is an aggressive hematologic malignancy that can respond well to initial treatment, but relapse remains a significant concern - particularly in adults. Studies show that up to 30 - 50% of patients may relapse, with a considerable proportion doing so within the first year after diagnosis. The most common site of relapse is the bone marrow, where leukemic cells often re-emerge. Other key sites include the central nervous system (CNS) and testes, particularly in patients who may not have received adequate prophylactic therapy. Risk factors for early relapse include older age, poor initial response to therapy, high leukemic burden, and unfavorable genetic markers. Understanding these risks and identifying relapse early is crucial for timely intervention and improved patient outcomes.

Thank you for joining us in this important discussion. We hope this session helped clarify the complexities of early relapse in B-cell ALL and highlighted the importance of vigilance in post-remission care. Stay tuned for more insightful and educational videos where we continue to explore evolving topics in hematology and oncology. Don’t forget to subscribe and share with colleagues who may benefit from this knowledge.

See More Webinars @ Hidoc Webinars